Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon Extension in Parkinson's Disease
NCT03185481Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jul 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tavapadon in Parkinson's disease (PD), sponsored by Pfizer. Started Jul 2017; status: terminated.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03185481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185481.